Abstracts tagged "depression"

Abstract Number: 1667 • ACR Convergence 2021
Efficacy of Plasma Phosphoethanolamine as a Biomarker for Rheumatoid Arthritis-associated Depression
Yusuke Miwa¹, Yoshiaki Ohashi², Hajime Tomatsu³ and Yuko Mitamura⁴, ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²HMT Biomedical Inc., Yokohama, Japan, ³HMT Biomedical Inc., Chuo, Japan, ⁴Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Shinagawa-ku, Japan
Background/Purpose: The odds of patients with rheumatoid arthritis (RA) experiencing depression is 1.42 (95% CI: 1.3–1.5; approximately 15% of patients) compared with healthy individuals. Diagnosis…
Abstract Number: 0236 • ACR Convergence 2021
Maternal Attachment, Anxiety and Depressive Symptoms in Pregnant Women with Rheumatic Diseases
Luis Gerardo Espinosa-Banuelos¹, Diana Carolina Rubio Torres², Maria Corral², Cassandra Skinner Taylor², Lorena Perez-Barbosa², Luz Fernanda Gutierrez Leal², Abraham Yair Lujano-Negrete³, Jesus Cardenas-de La Garza² and Dionicio Galarza-Delgado², ¹Faculty of Medicine and University Hospital Dr. Jose Eleuterio Gonzalez, UANL, Monterrey, Mexico, ²Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, ³Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico
Background/Purpose: Untreated perinatal anxiety symptomatology can be related to symptoms of anxiety and depression during the postpartum. The psychological bond created by the mother between…
Abstract Number: 1672 • ACR Convergence 2021
Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA
Susan Bartlett¹, Dana DiRenzo², Michelle Jones³ and Clifton Bingham², ¹McGill University, Montréal, QC, Canada, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Rheumatic diseases (RD) are chronic conditions that require potent immunosuppressants to control systemic inflammation. Fears associated with increased vulnerability from being on immunosuppressants plus…
Abstract Number: 0308 • ACR Convergence 2021
Sleep Disorders and Serum Brain-derived Neurotrophic Factor Levels in Patients with Primary Sjögren’s Syndrome
Yaxin Han¹, Li Long², Xixi Chen², Qing Peng², GUO TANG³, Jiajun Liu² and Yan Liu², ¹The People's Hospital of Wenjiang,China; Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China；Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China (People's Republic), ²Department of Rheumatology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China (People's Republic), ³Chongqing Bishan People's Hospital, Chongqing, China (People's Republic)
Background/Purpose: This study aimed to evaluate the sleep quality and its influenced factors in patients with primary Sjögren's syndrome (pSS), and another purpose is to…
Abstract Number: 1673 • ACR Convergence 2021
Riding Multiple Waves of Uncertainty: Real World Canadian RA Patient Outcomes over 1 Year of COVID-19 Restrictions
Orit Schieir¹, Susan Bartlett², Marie-France Valois², Louis Bessette³, Gilles Boire⁴, Glen Hazlewood⁵, Carol Hitchon⁶, Edward Keystone⁷, Janet Pope⁸, Diane Tin⁹, Carter Thorne¹⁰, Vivian Bykerk¹¹ and CATCH Investigators¹², ¹Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: During the COVID-19 pandemic, Canadians adults with RA faced considerable uncertainty due to greater risk of infection, hospitalization, changing access to RA medications, and…
Abstract Number: 0627 • ACR Convergence 2021
Increasing Rates of Standardized Depression Screening in Adolescents and Young Adults with Childhood-Onset Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Emily Datyner¹, Manda Mitchell¹, Brooke Fine¹, Barron Patterson¹, T. Brent Graham¹ and Alaina Davis², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt Universty Medical Center, Nashville, TN
Background/Purpose: Depression is common and adversely affects health outcomes in adolescents and young adults with childhood-onset systemic lupus erythematous (cSLE).1,2 The aim of our quality…
Abstract Number: 0655 • ACR Convergence 2021
Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis
Rosa Morlà¹, Beatriz Frade-Sosa², Núria Sapena³, Roberto Gumucio², Raimon Sanmarti² and Jose A Gomez-Puerta², ¹Hospital Universitari Clinic de Barcelona, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) is frequently associated with different comorbidities. Depression and fatigue are common in RA patients with a prevalence of 17-39-%(1) and 40%(2)…
Abstract Number: 0725 • ACR Convergence 2021
Efficacy of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Knee or Hip: A Post Hoc Subgroup Analysis of Patients from a Randomized, NSAID-Controlled Study with a History of Depression, Anxiety, or Insomnia
Philip Mease¹, Theresa Mallick-Searle², Elizabeth Johnston³, Lars Viktrup³, Dominique Menuet⁴, Ruoyong Yang⁵ and Robert Fountaine⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Stanford Health Care, Redwood City, ³Eli Lilly and Company, Indianapolis, IN, ⁴Pfizer SAS, Paris, France, ⁵Pfizer Inc., New York, NY, ⁶Pfizer Inc., Groton, CT
Background/Purpose: Tanezumab is a monoclonal antibody directed against nerve growth factor that is under study to treat moderate to severe chronic pain associated with osteoarthritis…
Abstract Number: 0736 • ACR Convergence 2021
Decrease in Prevalence of Self-Reported Anxiety or Depression in Persons with Osteoarthritis After Total Knee Arthroplasty: The BEST KNEE Cohort Study
Owen Krystia, Lauren King, Esther Waugh and Gillian Hawker, University of Toronto, Toronto, ON, Canada
Background/Purpose: While anxiety and depression are highly prevalent in persons with symptomatic knee osteoarthritis (OA), few studies have assessed the effect of treatment of knee…
Abstract Number: 0774 • ACR Convergence 2021
The Impact of Patient/Provider Discordance on Changes on Mood and Behavior in Adolescents with Systemic Lupus Erythematosus
Zanab Mian¹, Terrence Calistro², Kimberly Rapoza², Shari Berkowitz², Tamar Rubinstein³, Kathleen Kenney-Riley² and Joyce Hui-Yuen⁴, ¹Cohen Children's Medical Center, New Hyde Park, NY, ²Mercy College, Dobbs Ferry, NY, ³Albert Einstein College of Medicine, White Plains, NY, ⁴Cohen Childrens Medical Center, New Hyde Park, NY
Background/Purpose: Discordance between physicians’ and patients’ perceptions of disease severity can negatively impact treatment and disease outcomes; this has not yet been studied in children…
Abstract Number: 0872 • ACR Convergence 2021
Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
Sudha Raghunath¹, Yifat Glikmann-Johnston¹, Emma Guymer¹, Eric Morand², Julie Stout¹ and Alberta Hoi³, ¹Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Cognitive dysfunction (CD) is reported to affect approximately 40% of SLE patients (1). Mood disorders have been associated with both cognitive symptoms and cognitive…
Abstract Number: 0878 • ACR Convergence 2021
Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression
Eleni Papachristodoulou¹, Loukas Kakoullis¹, Savvas Psarelis², Victor Hajiroussos³, Costas Christophi⁴ and Konstantinos Parperis¹, ¹University of Cyprus Medical School, Nicosia, Cyprus, ²Nicosia General Hospital/University of Cyprus Medical Schooll, Nicosia, Cyprus, ³Ygia Polyclinic Hospital, Limassol, Cyprus, ⁴Cyprus University of Technology, Limassol, Cyprus
Background/Purpose: The need for readily available markers of SLE activity has led to the evaluation of laboratory parameters, such as the neutrophil to lymphocyte ratio…
Abstract Number: 0547 • ACR Convergence 2020
Transgender Patients in the Rheumatology Setting
Chantelle Carneiro¹, Jessica Chee², Karen Beattie² and Kimberly Legault², ¹McMaster University, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada
Background/Purpose: Minimal medical research exists regarding transgender patients, particularly within the field of rheumatology. A few case reports note that male to female transitions may…
Abstract Number: 1806 • ACR Convergence 2020
The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus
Erik Anderson¹, Ying Jin², Sara Goodwin², Julien Roeser³, Richard Furie⁴, Cynthia Aranow⁵, Bruce Volpe⁵, Betty Diamond⁶ and Meggan Mackay⁷, ¹Feinstein Institutes for Medical Research, New York, NY, ²Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Northwell Health, Manhasset, NY, ⁷Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Type I IFN contributes to SLE pathogenesis and stimulates the kynurenine/tryptophan (KYN/TRP) pathway, producing elevated quinolinic acid (QA) levels relative to kynurenic acid (KA)…
Abstract Number: 0551 • ACR Convergence 2020
Physical Performance as a Mediator of the Association Between Depression and Pain in Knee Osteoarthritis
Alan Rathbun¹, Elizabeth Stuart², Michelle Shardell¹, Trang Nguyen², Alice Ryan¹, Joseph Gallo², Michelle Yau³, Megan Schuler⁴ and Marc Hochberg¹, ¹University of Maryland School of Medicine, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Hinda and Arthur Marcus Institute for Aging Research, Boston, MA, ⁴RAND Corporation, Boston, MA
Background/Purpose: Depression is common in knee osteoarthritis (OA), and leads to reduced physical function, which may mediate the effect of depression on pain. However, research…

« Previous Page
1
…
4
5
6
7
8
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].